NextCure (NXTC) Stock Price

NextCure Price

NASDAQ·CLOSED
4.14USD-0.89 (-19.29 %)
Market closed

For NextCure, the net margin of -148.3% is up versus -531.5% a few years ago. The consensus 12-month price target for NextCure is 18.36 USD, about 342.9% above where the stock trades today. Of 9 analysts, 8 rate the stock a buy — an overall Buy consensus. The stock trades about 159% above its 52-week low.

NextCure stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of NextCure over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how NextCure stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing NextCure's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

NextCure Stock Price History
DateNextCure Price
7/31/20264.14 USD
7/30/20265.03 USD
7/29/20265.57 USD
7/27/20264.77 USD
7/23/20264.18 USD
7/22/20264.40 USD
7/21/20265.11 USD
7/20/20265.40 USD
7/17/20265.99 USD
7/16/20266.17 USD
7/15/20266.63 USD
7/14/20266.58 USD
7/13/20262.02 USD
7/10/20261.97 USD
7/9/20262.00 USD
7/8/20261.60 USD
7/7/20261.78 USD
7/6/20261.88 USD
7/2/20261.88 USD
7/1/20261.95 USD
6/30/20261.60 USD
6/29/20261.75 USD
6/26/20261.64 USD
6/25/20261.65 USD
6/24/20261.77 USD
6/23/20261.81 USD
6/22/20261.77 USD
6/18/20262.02 USD
6/17/20262.20 USD
6/16/20261.96 USD
6/15/20261.98 USD
6/12/20262.08 USD
6/11/20262.23 USD
6/10/20262.23 USD
6/9/20262.33 USD
6/8/20262.79 USD
6/5/20262.95 USD
6/4/20263.19 USD
6/3/20263.15 USD
6/2/20263.40 USD
6/1/20263.38 USD
5/29/20263.38 USD
5/28/20263.49 USD
5/27/20263.31 USD
5/26/20263.83 USD
5/22/20264.27 USD
5/21/20265.56 USD
5/20/20265.26 USD
5/19/20264.98 USD
5/18/20265.04 USD
5/15/20265.31 USD
5/14/20265.59 USD
5/13/20265.34 USD
5/12/20265.33 USD
5/11/20265.33 USD
5/8/20265.32 USD
5/7/20265.55 USD
5/6/20265.84 USD
5/5/20265.08 USD
5/4/20264.86 USD
5/1/20265.10 USD
4/30/20265.02 USD
4/29/20264.87 USD
4/28/20265.04 USD
4/27/20265.24 USD
4/24/20265.74 USD
4/23/20266.82 USD
4/22/20266.54 USD
4/21/20265.98 USD
4/20/20266.38 USD
4/17/20265.63 USD
4/16/20266.00 USD
4/15/20266.86 USD
4/14/20266.96 USD
4/13/20266.72 USD
4/10/20266.35 USD
4/9/20266.11 USD
4/8/20266.08 USD
4/7/20266.07 USD
4/6/20266.01 USD
4/2/20265.84 USD
4/1/20265.74 USD
3/31/20265.82 USD
3/30/20265.40 USD
3/27/20265.46 USD
3/26/20265.52 USD
3/25/20265.56 USD
3/24/20265.42 USD
3/23/20265.68 USD
3/20/20265.45 USD
3/19/20265.50 USD
3/18/20266.33 USD
3/17/20266.72 USD
3/16/20266.52 USD
3/13/20266.91 USD
3/12/20267.37 USD
3/11/20267.41 USD
3/10/20266.93 USD
3/9/20266.82 USD
3/6/20266.75 USD
3/5/20266.96 USD
3/4/20266.87 USD
3/3/20266.57 USD
3/2/20266.83 USD
2/27/20266.93 USD
2/26/20267.09 USD
2/25/20267.11 USD
2/24/20267.01 USD
2/23/20267.21 USD
2/20/20267.49 USD
2/19/20267.78 USD
2/18/20267.15 USD
2/17/20267.20 USD
2/13/20267.14 USD
2/12/20267.22 USD
2/11/20266.81 USD
2/10/20266.68 USD
2/9/20266.46 USD
2/6/20266.05 USD
2/5/20266.05 USD
2/4/20266.44 USD
2/3/20266.11 USD
2/2/20265.96 USD
1/30/20265.92 USD
1/29/20265.68 USD
1/28/20265.83 USD
1/27/20266.06 USD
1/26/20266.65 USD
1/23/20266.50 USD
1/22/20266.90 USD
1/21/20267.08 USD
1/20/20267.23 USD
1/16/20267.04 USD
1/15/20267.02 USD
1/14/20267.07 USD
1/13/20267.28 USD
1/12/20267.29 USD
1/9/20267.29 USD
1/8/20267.41 USD
1/7/20267.62 USD
1/6/20267.08 USD
1/5/20267.41 USD
1/2/20267.24 USD
12/31/20257.74 USD
12/30/20257.62 USD
12/29/20257.20 USD
12/26/20256.96 USD
12/24/20256.97 USD
12/23/20256.92 USD
12/22/20256.30 USD
12/19/20256.20 USD
12/18/20255.83 USD
12/17/20255.73 USD
12/16/20256.06 USD
12/15/20256.25 USD
12/12/20256.07 USD
12/11/20256.21 USD
12/10/20256.37 USD
12/9/20256.07 USD
12/8/20256.16 USD
12/5/20256.72 USD
12/4/20256.94 USD
12/3/20256.56 USD
12/2/20256.84 USD
12/1/20257.31 USD
11/28/20257.68 USD
11/26/20257.43 USD
11/25/20257.61 USD
11/24/20257.69 USD
11/21/20255.73 USD
11/20/20255.02 USD
11/19/20255.10 USD
11/18/20255.45 USD
11/17/20255.53 USD
11/14/20255.39 USD
11/13/20255.32 USD
11/12/20255.06 USD
11/11/20254.64 USD
11/10/20254.63 USD
11/7/20254.88 USD
11/6/20255.35 USD
11/5/20255.25 USD
11/4/20255.26 USD
11/3/20256.53 USD
10/31/20256.87 USD
10/30/20256.68 USD
10/29/20256.53 USD
10/28/20255.64 USD
10/27/20255.05 USD
10/24/20255.02 USD
10/23/20254.85 USD
10/22/20254.92 USD
10/21/20256.43 USD
10/20/20255.90 USD
10/17/20256.50 USD
10/16/20254.74 USD
10/15/20253.71 USD
10/14/20253.66 USD
10/13/20253.46 USD
10/10/20253.63 USD
10/9/20253.56 USD
10/8/20253.73 USD
10/7/20253.34 USD
10/6/20253.27 USD
10/3/20253.18 USD
10/2/20253.14 USD
10/1/20253.10 USD
9/30/20253.19 USD
9/29/20253.16 USD
9/26/20253.11 USD
9/25/20253.15 USD
9/24/20253.13 USD
9/23/20253.01 USD
9/22/20253.03 USD
9/19/20253.07 USD
9/18/20253.08 USD
9/17/20253.03 USD
9/16/20253.09 USD
9/15/20253.00 USD
9/12/20252.94 USD
9/11/20252.97 USD
9/10/20252.99 USD
9/9/20252.76 USD
9/8/20252.68 USD
9/5/20252.64 USD
9/4/20252.69 USD
9/3/20252.71 USD
9/2/20252.69 USD
8/29/20252.74 USD
8/28/20252.80 USD
8/27/20252.85 USD
8/26/20252.85 USD
8/25/20252.84 USD
8/22/20252.80 USD
8/21/20252.79 USD
8/20/20252.80 USD
8/19/20252.77 USD
8/18/20252.87 USD
8/15/20252.79 USD
8/14/20252.81 USD
8/13/20252.83 USD
8/12/20252.64 USD
8/11/20252.62 USD
8/8/20252.65 USD
8/7/20252.78 USD
8/6/20252.81 USD
8/5/20252.83 USD
8/4/20252.75 USD
Access this data via the Eulerpool API
Get Free API Key

NextCure Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
0.00 USD
-67.64 M USD
-62.72 M USD
Jan 1, 2024
0.00 USD
-59.75 M USD
-55.65 M USD
Jan 1, 2025
0.00 USD
-57.62 M USD
-55.84 M USD
Jan 1, 2026 (e)
3.30 M USD
-45.25 M USD
-19.80 M USD
Jan 1, 2027 (e)
7.00 M USD
-54.83 M USD
-15.95 M USD
Jan 1, 2028 (e)
10.30 M USD
-63.50 M USD
-11.62 M USD
Jan 1, 2029 (e)
22.60 M USD
-58.75 M USD
-9.98 M USD
Jan 1, 2030 (e)
39.70 M USD
-14.08 M USD
-7.13 M USD

NextCure Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 12:17 PM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
2017201820192020202120222023202420252026e2027e2028e2029e2030e
––6.0022.00–––––3.007.0010.0022.0039.00
–––266.67––––––133.3342.86120.0077.27
––-450.00100.00–––––-66.67-28.57-20.00-9.09-5.13
-2.00-1.00-27.0022.00-4.00-4.00-3.00-2.00-2.00-2.00-2.00-2.00-2.00-2.00
-15.00-23.00-37.00-41.00-70.00-75.00-67.00-59.00-57.00-45.00-54.00-63.00-58.00-14.00
––-616.67-186.36–––––-1,500.00-771.43-630.00-263.64-35.90
-15.00-22.00-33.00-33.00-69.00-69.00-62.00-55.00-55.00-19.00-15.00-11.00-9.00-7.00
–46.6750.00–109.09–-10.14-11.29–-65.45-21.05-26.67-18.18-22.22
3.5110.042.292.302.302.312.332.333.513.513.513.513.513.51
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales NextCure generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue NextCure retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare NextCure's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares NextCure has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against NextCure's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

NextCure stock margins

The NextCure margin analysis displays the gross margin, EBIT margin, as well as the profit margin of NextCure. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for NextCure.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
100.00 %
- %
- %
Jan 1, 2022
100.00 %
- %
- %
Jan 1, 2023
100.00 %
- %
- %
Jan 1, 2024
100.00 %
- %
- %
Jan 1, 2025
100.00 %
- %
- %
Jan 1, 2026 (e)
100.00 %
-1,371.33 %
-599.89 %
Jan 1, 2027 (e)
100.00 %
-783.21 %
-227.80 %
Jan 1, 2028 (e)
100.00 %
-616.46 %
-112.79 %

NextCure Stock Revenue, EBIT, Earnings per Share

The NextCure earnings per share therefore indicates how much revenue NextCure has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.00 USD
-30.72 USD
-30.12 USD
Jan 1, 2022
0.00 USD
-32.80 USD
-30.00 USD
Jan 1, 2023
0.00 USD
-29.08 USD
-26.97 USD
Jan 1, 2024
0.00 USD
-25.60 USD
-23.85 USD
Jan 1, 2025
0.00 USD
-16.44 USD
-15.93 USD
Jan 1, 2026 (e)
1.23 USD
-12.91 USD
-7.39 USD
Jan 1, 2027 (e)
2.61 USD
-15.64 USD
-5.95 USD
Jan 1, 2028 (e)
3.84 USD
-18.11 USD
-4.34 USD

NextCure business model & stock analysis

NextCure Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

NextCure Employees
Details
Date
NextCure Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

NextCure Segments

NextCure Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

NextCure historical P/E ratio, EBIT multiple, and P/S ratio

NextCure annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

NextCure shares outstanding

The number of shares of NextCure was 3.51 M in 2025. This indicates how many shares NextCure is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
2.30 M Stocks
Jan 1, 2022
2.31 M Stocks
Jan 1, 2023
2.33 M Stocks
Jan 1, 2024
2.33 M Stocks
Jan 1, 2025
3.51 M Stocks
Jan 1, 2026 (e)
3.51 M Stocks
Jan 1, 2027 (e)
3.51 M Stocks
Jan 1, 2028 (e)
3.51 M Stocks

NextCure stock splits

In NextCure's history, there have been no stock splits.

Current NextCure forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
88.89 % (8)
Hold
11.11 % (1)
Sell
0.00 % (0)
12M Price Target
18.36
Last Price
4.14
Currency
USD
12M Return Potential
342.94 %
LTM Return
0 %

NextCure Analyst Rating Actions

DateFirmActionRatingReliability
11/7/2025
Ladenburg Thalmann
Ladenburg Thalmann
UpgradeNeutralBuy–
7/15/2025
Piper Sandler
Piper Sandler
MaintainedOverweight51
7/1/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/17/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
3/7/2025
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
11/11/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
8/2/2024
Needham
Needham
MaintainedBuy70
6/3/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/31/2024
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
5/3/2024
Needham
Needham
MaintainedBuy70

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

NextCure Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/5/2026-1.97USD-0.00USD-2026 Q2
4/29/2026-1.85USD-0.00USD-2026 Q1
3/4/2026-2.47USD-0.00USD-2025 Q4
5/2/2024-0.60USD-0.00USD-2024 Q1
2/29/2024-0.57USD-0.00USD-2023 Q4
8/2/2023-0.65USD-0.00USD-2023 Q2
5/3/2023-0.65USD-0.00USD-2023 Q1
11/3/2022-0.64USD-0.00USD-2022 Q3
8/4/2022-0.73USD-0.00USD-2022 Q2
5/5/2022-0.68USD-0.00USD-2022 Q1

EESG©

Eulerpool ESG Scorecard© for the NextCure stock

69/100
74
Environment
78
Social
56
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

NextCure shareholder structure

% Name
12.63567%
Simcere Zaiming, Inc
Simcere Zaiming, Inc
6.48735%
Squadron Capital Management LLC
Squadron Capital Management LLC
0.02571%
BlackRock Fund Advisors
BlackRock Fund Advisors

NextCure Beneficial Ownership Filings (SEC 13D/G)

Free Float
62.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
11.10%
Dr. Michael F. Powell (“Powell”)
Dr. Michael F. Powell (“Powell”)
SEC ↗
11.10%
Dr. Anand Mehra (“Mehra”)
Dr. Anand Mehra (“Mehra”)
SEC ↗
11.00%
Logos GP LLC
Logos GP LLC
SEC ↗
11.00%
Logos Global Master Fund LP
Logos Global Master Fund LP
SEC ↗
11.00%
Logos Global Management GP LLC
Logos Global Management GP LLC
SEC ↗
11.00%
Arsani William
Arsani William
SEC ↗
9.99%
Ikarian Capital, LLC
Ikarian Capital, LLC
SEC ↗
9.99%
Affinity Asset Advisors, LLC
Affinity Asset Advisors, LLC
SEC ↗
9.90%
Squadron Master Fund LP
Squadron Master Fund LP
SEC ↗
9.40%
Simcere Zaiming, Inc.
Simcere Zaiming, Inc.
SEC ↗

NextCure Executives and Management Board

13 members · avg. age 63 · 23 % women

MR

Mr. Michael Richman (64)

President, Chief Executive Officer, Director · since 2015

1.51 M USD

Management

SC

Mr. Steven Cobourn (62)

Chief Financial Officer · since 2018

993,341.00 USD
SL

Dr. Solomon Langermann (65)

Chief Scientific Officer

882,845.00 USD
TM

Dr. Timothy Mayer (61)

Chief Operating Officer

872,206.00 USD
KS

Mr. Kevin Shaw (51)

Senior Vice President, General Counsel

–
SK

Dr. Sourav Kundu (65)

Senior Vice President - Development and Manufacturing

–
UG

Dr. Udayan Guha (53)

Chief Medical Officer

–

Board of Directors

DK

Dr. David Kabakoff (77)

Independent Chairman of the Board

111,325.00 USD
SW

Mr. Stephen Webster (64)

Independent Director

77,520.00 USD
EJ

Dr. Elaine Jones (70)

Independent Director

75,383.00 USD
JH

Dr. John Houston (65)

Independent Director

67,520.00 USD
EF

Dr. Ellen Feigal (71)

Independent Director

64,883.00 USD
AB

Dr. Anne Borgman (57)

Independent Director

63,883.00 USD

NextCure Supply Chain

Frequently asked questions about NextCure

Analysts currently set an average price target of 18.02 USD for the NextCure stock (median: 18.36 USD), implying +334.7 % versus the latest price. The consensus is based on 9 analyst ratings.

NextCure Analyst Price Targets 2026

9 analysts currently rate the NextCure stock: 8 recommend buying, 1 holding and 0 selling. For 2026, analysts expect NextCure to generate revenue of 3.30 M USD and earnings per share of -5.65 USD.

NextCure Analyst Price Targets 2026

Converted at the current exchange rate, the NextCure share trades at 3.59 EUR (4.14 USD).

The NextCure share (NXTC) is listed on 4 stock exchanges, including: NASDAQ (NXTC), Frankfurt (2US.F), München (2US.MU), Düsseldorf (2US.DU).

No history available for NextCure.

The expected revenue of NextCure is 3.30 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of NextCure is -19.80 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of NextCure is currently -0.73. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the NextCure stock.

The price-to-sales ratio (P/S) of NextCure is currently 4.40. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the NextCure stock.

The Eulerpool Quality Score for NextCure is 2/10.

The ISIN of NextCure is US65343E2072. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of NextCure is A2PHHE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of NextCure is NXTC. The ticker symbol is used to trade NextCure shares on the stock exchange.

NextCure paid dividends every year for the past 0 years.

NextCure is assigned to the 'Health' sector.

The dividends of NextCure are distributed in USD.

All fundamentals and in-depth analysis of NextCure

Our stock analysis for NextCure stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of NextCure. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

NextCure Stock
NextCure Revenue→
NextCure Stock
NextCure Net Income→
NextCure Stock
NextCure P/E→
NextCure Stock
NextCure P/S→
NextCure Stock
NextCure EBIT→
NextCure Stock
NextCure Dividend→
NextCure Stock
NextCure Directors Dealings→
NextCure Stock
NextCure Stocks→
NextCure Stock
NextCure Market capitalization→
NextCure Stock
NextCure Debt→
NextCure Stock
NextCure Liabilities→
NextCure Stock
NextCure Equity→
NextCure Stock
NextCure AAQS→
NextCure Stock
NextCure Employees→
NextCure Stock
NextCure ROE→
NextCure Stock
NextCure ROA→
NextCure Stock
NextCure ROCE→
NextCure Stock
NextCure News→
NextCure Stock
NextCure Analyst Price Targets→

Health Stocks

Nextleaf SolutionsNextCell PharmaNfl Biosciences SASNextBioMedical CoNGeneBio CoNexstim OyjNgl Fine ChemNeximmuneNGS GroupNexien BiopharmaNiagen BioscienceNexgelAll Stocks A–Z →